What Pandemic? Joinn Lab Posts Bumper Profit Despite Covid Disruptions

Less affected by Covid-control measures that have clobbered many Chinese businesses, the pre-clinical contract research organization’s profit more than doubled in the first three quarters of 2022.
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×